Zacks: Analysts Expect Axovant Sciences Ltd (AXON) Will Announce Earnings of -$0.49 Per Share

Brokerages expect Axovant Sciences Ltd (NASDAQ:AXON) to report ($0.49) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Axovant Sciences’ earnings, with the highest EPS estimate coming in at ($0.25) and the lowest estimate coming in at ($0.57). Axovant Sciences reported earnings of ($0.48) per share during the same quarter last year, which indicates a negative year over year growth rate of 2.1%. The business is scheduled to report its next quarterly earnings report on Tuesday, February 13th.

According to Zacks, analysts expect that Axovant Sciences will report full-year earnings of ($2.17) per share for the current fiscal year, with EPS estimates ranging from ($2.35) to ($1.80). For the next fiscal year, analysts forecast that the business will report earnings of ($1.88) per share, with EPS estimates ranging from ($2.65) to ($1.22). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Axovant Sciences.

Axovant Sciences (NASDAQ:AXON) last issued its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.64) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.09).

A number of brokerages recently commented on AXON. Zacks Investment Research upgraded Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a research report on Wednesday. Chardan Capital upgraded Axovant Sciences from a “sell” rating to a “neutral” rating and set a $2.50 target price on the stock in a research report on Wednesday, January 10th. BidaskClub upgraded Axovant Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, October 5th. Oppenheimer reiterated a “hold” rating on shares of Axovant Sciences in a research report on Sunday, November 12th. Finally, ValuEngine lowered Axovant Sciences from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $13.61.

Shares of Axovant Sciences (NASDAQ:AXON) traded down $0.04 during midday trading on Wednesday, reaching $2.03. The company had a trading volume of 539,120 shares, compared to its average volume of 2,180,000. The stock has a market capitalization of $218.65 and a price-to-earnings ratio of -0.88. Axovant Sciences has a 52-week low of $2.00 and a 52-week high of $27.98. The company has a current ratio of 5.94, a quick ratio of 5.94 and a debt-to-equity ratio of 0.34.

A number of large investors have recently made changes to their positions in the business. Hikari Power Ltd acquired a new position in Axovant Sciences in the fourth quarter valued at approximately $377,000. Cubist Systematic Strategies LLC acquired a new position in shares of Axovant Sciences during the 3rd quarter worth approximately $117,000. OxFORD Asset Management LLP raised its stake in shares of Axovant Sciences by 842.1% during the 3rd quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock worth $5,838,000 after buying an additional 777,505 shares during the period. Wells Fargo & Company MN raised its stake in shares of Axovant Sciences by 135.6% during the 3rd quarter. Wells Fargo & Company MN now owns 53,695 shares of the biotechnology company’s stock worth $369,000 after buying an additional 30,905 shares during the period. Finally, Eagle Asset Management Inc. acquired a new position in shares of Axovant Sciences during the 3rd quarter worth approximately $4,471,000. 96.95% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Expect Axovant Sciences Ltd (AXON) Will Announce Earnings of -$0.49 Per Share” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.americanbankingnews.com/2018/01/31/zacks-analysts-expect-axovant-sciences-ltd-axon-will-announce-earnings-of-0-49-per-share.html.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Get a free copy of the Zacks research report on Axovant Sciences (AXON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply